

# A Study of Role of Prophylactic Magnesium Sulphate in Severe Preeclampsia in Preventing Eclampsia and Neonatal Outcome

Dr. P. Rajani<sup>1</sup>, Dr. M. Radhika<sup>2\*</sup>, Dr. R. Sarla Devi<sup>3</sup>, Dr. T. Nirmala Kumari<sup>4</sup>

<sup>1</sup>Assistant Professor, Department of Obstetrics and Gynaecology, Kakatiya Medical College, Rangam Peta Street, Telangana 506007, India

<sup>2</sup>Assistant Professor, Department of Obstetrics and Gynaecology, Kakatiya Medical College, Rangam Peta Street, Telangana 506007, India

<sup>3</sup>Professor & HOD, Department of Obstetrics and Gynaecology, Kakatiya Medical College, Rangam Peta Street, Telangana 506007, India

<sup>4</sup>Professor, Department of Obstetrics and Gynaecology, Kakatiya Medical College, Rangam Peta Street, Telangana 506007, India

DOI:10.21276/sijog.2019.2.7.2

| Received: 29.06.2019 | Accepted: 07.07.2019 | Published: 17.07.2019

\*Corresponding author: Dr. M. Radhika

## Abstract

The study included more of booked cases compared to unbooked. In booked cases most of them belonged to group to whom magnesium sulphate was not given (70% not given vs 59% given) and while in unbooked cases most of them were in group who received magnesium indicating poor control of blood pressure in unbooked cases. This confirms the high incidence of pre eclampsia in primigravida (69% given and 66% not given), more common in young women. The inclusion of more of preterm pregnancies represents the fact that termination of pregnancy is definitive treatment of pre eclampsia. Among the vaginal deliveries the instrumental delivery was significantly more in magnesium sulphate given group representing the tocolytic effect of magnesium sulphate. The complications of severe preeclampsia like eclampsia, pulmonary oedema and renal failure occurred more in group not given magnesium sulphate (2%,1%,1% given vs 11%, 3%, 4% not given) respectively and incidence of abruption and DIC in is almost similar in both groups (4% and 1% Vs 3% and 1%). Eclampsia is a grave complication of severe preeclampsia occurred more in the group not given magnesium sulphate compared to group given magnesium sulphate (11% vs 2%) indicating that intervention with magnesium sulphate has better maternal out come when given to women with severe pre eclampsia. The symptoms of toxicity like loss of deep tendon reflexes, oliguria and other side effects like nausea, head ache, flushing and vomiting had higher incidence in magnesium sulphate administered group. Nearly 40%-50% of new borns from both groups had good Apgar of 7-10 (40% given and 46% not given) respectively. Women with 3-6 Apgar were more in magnesium sulphate administered group (32% vs 10%) respectively in given and not given groups. Both groups had equal NICU admissions. When new born of more than 32 weeks, the salvageable neonates admitted to NICU were considered, the outcome was better in group given magnesium sulphate with no deaths pointing towards role of magnesium sulphate in improving fetal survival.

**Keywords:** Eclampsia, Magnesium sulphate, Pregnancy, Outcome, Complications, Neonatal outcome.

**Copyright @ 2019:** This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

## INTRODUCTION

Hypertensive disorders complicate 5 to 10% of the pregnancies, among which preeclampsia and eclampsia are important causes of maternal morbidity and mortality [1]. Pre-eclampsia complicates 5 to 7 % of all the pregnancies out of which 3.3% develop severe preeclampsia [2] and less than 1% land into eclampsia [3] which is the second most common cause of maternal and perinatal morbidity in under privileged population [4]. In eclampsia maternal mortality is 10% and fetal mortality is 20 to 30 % [5]. In developed countries eclampsia is rare, affecting around 1 in 2000 deliveries [6] while in developing countries estimates varies from 1 in 100 to 1 in 1700 [7, 8]. Worldwide an estimated

600,000 women die each year of pregnancy related causes [9], with 99% of these deaths occurring in developing countries. Preeclampsia and eclampsia account for about 50,000 maternal deaths a year [10]. Hence early identification and interventions are mandatory to overcome these complications of preeclampsia. In 1927 Alton and Lincoln [11] used Magnesium sulphate intrathecally, since then it was used in the treatment of eclampsia.

The present study is cross sectional interventional study conducted to determine the role or efficacy of magnesium sulphate as a prophylactic agent in all cases of severe preeclampsia in preventing

eclampsia. In many institutes, routine protocol is to administer magnesium sulphate after the onset of imminent signs or convulsions. The goal is to prevent seizures and its complications on mother and fetus by early detection and intervention before onset of imminent signs and symptoms of eclampsia.

## MATERIAS & METHODS

The study was undertaken from January to December 2018 in Department of obstetrics and gynaecology at Kakatiya medical college, warangal which is a teaching hospital and a tertiary referral centre as well. The study is a cross sectional interventional type of study.

### Inclusion Criteria

All antenatal women both primi and multi gravid satisfying the diagnostic criteria of severe pre eclampsia, were included. These women were either in labour or those in whom termination has been decided and free of any imminent signs of eclampsia. As appearance of imminent sign is a surest indication for administration of magnesium sulphate in our institution, women with imminent signs requiring magnesium sulphate were excluded from study.

### Criteria for Severe Preeclampsia

- Severe hypertension, BP > 160/110 mm of Hg or more.
- Proteinuria > 5gm/24 hr or 2+ or more in random urine samples.
- Elevated serum creatinine levels > 0.8mg/dl.
- Pulmonary oedema.
- Oliguria < 500 ml/24 hrs.
- Micro angiopathic haemolysis.
- Thrombocytopenia with platelets < 1 lakh/cu mm<sup>3</sup>.
- Elevated ALT and AST.> 40 IU/L.
- Pain in the epigastrium or right upper quadrant.
- Symptoms of end organ involvement like headache, visual complaints or epigastric pain.

### Exclusion Criteria

Cases of severe preeclampsia with symptoms of imminent eclampsia, Cases of chronic hypertension with no superimposed pre eclampsia, Hypertension due

to other causes, epilepsy conductive cardiac failure, myasthenia gravis or other neuromuscular disorders.

### Method

About 100 women with severe pre eclampsia either in labour or in whom decision for termination has been taken were selected and history noted according to proforma and followed up till discharge. These women who received magnesium sulphate were compared with 100 women who were similarly followed and did not receive magnesium sulphate. The newborn of both groups were observed till discharge. In present study Pritchard's regimen was used, to administer magnesium sulphate as it is widely accepted and has been proven to be more effective and attain a good therapeutic serum values compared to other regimens and it's simpler to administer in a set up like ours.

Pritchard's regimen is administration of a loading dose of 4 gms of 20% magnesium sulphate intravenously into accessible peripheral vein generally cubital vein over 15-20 minutes followed by 10 gms of 50% magnesium sulphate deep intramuscular one half in each buttock. Followed by maintenance dose of magnesium sulphate 5gms of 50% solution of magnesium sulphate every fourth hourly for 24 hours from the start of first dose under strict monitoring for toxicity. Magnesium sulphate toxicity was monitored by clinical signs of loss of tendon reflexes, drowsiness, oliguria and respiratory distress. Serum magnesium levels were not monitored due to poor affordability of women in study. Magnesium sulphate was discontinued once toxic signs appeared. And calcium gluconate antidote was kept available. In group not given magnesium sulphate with severe pre eclampsia if women had convulsions or developed symptoms of imminent eclampsia like headache, epigastric pain, blurred vision the trial was stopped and was given magnesium sulphate and monitored.

## RESULTS

This study was conducted at Kakatiya medical college, warangal, to know the efficacy of magnesium sulphate as a prophylactic agent in all cases of severe preeclampsia in preventing eclampsia and its effects on neonates. The results were expressed in tables given below.

**Table-1: Distribution of total cases -booked and unbooked**

	Mgso4 – given	Mgso4- not given	Total
Booked	59 (59%)	70 (70%)	129
Un booked	41 (41%)	30 (30%)	71
Total	100 (100%)	100 (100%)	200

**Table-2: Age wise distribution**

AGE	Mgso4 -given	Mgso4-notgiven	Total
<21yrs	52 (52%)	23 (23%)	75
21-25yrs	46 (46%)	65 (65%)	111
>25yrs	2 (2%)	12 (12%)	14
Total	100 (100%)	100 (100%)	200

**Table-3: Case distribution among primigravida and multigravida**

	Mgso4 –given	Mgso4-not given	Total
Primi gravida	69 (69%)	66 (66%)	135
Gravida 2	25 (25%)	17 (17%)	42
Gravida 3 and more	6 (6%)	17 (17%)	23
Total	100 (100%)	100 (100%)	200

**Table-4: Case distribution according to gestational age at delivery**

	Mgso4 –given	Mgso4-not given	Total
Term gestation	48 (48%)	60 (60%)	108
33-36 weeks	37 (37%)	38 (38%)	75
28-32 weeks	15 (15%)	2 (2%)	17
Total	100 (100%)	100 (100%)	200

**Table-5: Comparison of onset of labour in vaginal deliveries**

	Mgso4-given	Mgso4 –not given
Spontaneous onset of labour	8 (16%)	7 (13.46%)
Induced labour	42 (84%)	45 (86.53%)
Total	50 (100%)	52 (100%)

**Table-6: Comparison of mode of delivery**

	Mgso4-given	Mgso4-not given	TOTAL
SPVD	35 (35%)	48 (48%)	83
INS	15 (15%)	4 (4%)	19
CS	50 (50%)	48 (48%)	98
TOTAL	100 (100%)	100 (100%)	200

**Table-7: Comparison of indications for cesarean section**

	Mgso4-given	Mgso4-not given	Total
Previous section	15 (30%)	13 (27.08%)	28
Fetal distress	19 (38%)	19 (39.58%)	38
Dystocia	13 (26%)	13 (27.08%)	26
UHTN	3 (6%)	3 (6.2%)	6
Total	50 (100%)	48 (100%)	98

**Table-8: maternal out come with respect to complications of severe pre eclampsia**

	Mgso4 –given	Mgso4-not given	Total
Eclampsia	2 (2%)	11 (11%)	13
Abruption	4 (4%)	3 (3%)	7
Renal failure	1 (1%)	3 (3%)	4
Pulmonary oedema	1 (1%)	4 (4%)	5
DIC	1 (9%)	1 (1%)	2
HELLP/MM	-	-	-

**Table-9: Comparison of incidence of eclampsia**

	Mgso4 –given	Mgso4 –not given	Total
Eclampsia	2 (2%)	11 (11%)	13
Eclampsia free	98 (98%)	89 (89%)	187
Total	100 (100%)	100 (100%)	200

**Table-10: Comparison of side effects with magnesium sulphate**

	Mgso4 –given	Mgso4-not given	Total
LDTR	22	-	22
Oliguria	24	12	36
RD	2	4	6
PPH	-	-	-
Other complaints N/V/F	20	6	26

**Table-11: Comparison of neonatal out come in both groups**

Apgar score at birth	Mgso4 –given	Mgso4-not given	Total
7-10	40 (40%)	46 (46%)	86
3-6	32 (32%)	10 (10%)	42
<3	24 (24%)	40 (40%)	64
Still birth	4 (4%)	4 (4%)	8
Total	100 (100%)	100 (100%)	200

**Table -12: Distribution of nicu admissions according to gestational age at delivery**

Gestational age of newborn	Mgso4-given	Mgso4 not given
32weeks and less	16 (45.71%)	29 (5.55%)
More than 32 weeks	19 (54.28%)	34 (94.44%)
Total	35 (100%)	36 (100%)

**Table-13: Outcome of total nicu admissions →32wks and 32 and less gestational age newborn**

	Mgso4 –given	Mgso4 – not given
Discharged	30(85.71%)	31(86.11%)
Dead	5(15.625%)	5(13.8%)
TOTAL	35 (100%)	36 (100%)

**Table-14: NICU out come in newborn more than 32 weeks**

	Mgso4 –given	Mgso4-not given
Discharged	19 (100%)	31 (91.18%)
Dead	0	3 (8.82%)
Total	19 (100%)	34 (100%)

## DISCUSSION

Eclampsia remains a complex and partially understood disease and its prophylaxis is the area of greatest controversy. Although magnesium sulphate is a proven anticonvulsant eclampsia, its role in prophylaxis is less certain. The present study included more number of booked cases compared to unbooked, as pre eclampsia being high risk pregnancy; women had regular antenatal visits and were referred early in pregnancy. And major part of booked cases formed a part of group not given magnesium sulphate, as their blood pressures were under control with good antenatal visits. Unbooked cases referred directly with high uncontrollable blood pressures constituted major part of magnesium sulphate administered group.

The women in the present study were mostly of age group less than 25years compared to above 25years age group respectively. Primigravida formed the major part of study in both groups. preeclampsia is known to occur more commonly in primigravida, where as in a study conducted by Omu *et al.*, [12] in the year 2007 Women in the age group of 31–40years were more likely to have severe preeclampsia compared with younger and older counterparts. In Altman Magpie trail 2004 [13] number of primigravida effected more compared to multi gravida. Women with severe preeclampsia required early termination of pregnancy. The term and preterm pregnancies were (48% and 60% vs 52% and 40%) in group given magnesium sulphate and not given respectively. This is comparable to studies conducted by the Magpie trail 2002 [14], Sohini Bhattacharya study [15].

As pre eclampsia being a high risk pregnancy, most of the women were terminated before onset of spontaneous labour. (91.3% in given and 88.8% in not given, required induction vs 8.6% in given and 11.11% in not given set into spontaneous labour) respectively in both groups. Administration of Magnesium sulphate did not affect the outcome of labour like rate of Cesarean section. This conforms to the previous studies. We had a Cesarean delivery rate of 50% in the group receiving magnesium sulphate. Indications being mostly fetal distress (19%), followed by previous cesarean section (17%) and dystocia (13%) and very few with uncontrolled blood pressure (3%). Results were similar in group not given magnesium sulphate. Similar to study by Sohini Bhattacharya [15] of 50% of cesarean section rate in group receiving magnesium sulphate mostly done in view of uncontrolled hypertension 42.8%.

Instrumental vaginal delivery rate was higher in magnesium sulphate group with 15% compared to other group 4% with a difference of 11% which is significant statistically indicating that magnesium sulphate has got a tocolytic effect on uterine activity which led to instrumental delivery. This is similar to results obtained in study by Sohini Bhattacharya [15] with more instrumental deliveries in group given magnesium sulphate (20% vs 4.2%).

In present study we had a much higher incidence of eclampsia in the severely preeclamptic mothers not receiving magnesium sulphate than the

group receiving it (11% versus 2%). The difference of 9% has been calculated to be statistically significant. This is comparable with the four large randomized trials discussed by Sibai BM showing a lower rate of eclampsia in those assigned to magnesium sulphate (0.6% versus 2.0%). Thus the number of women needed to treat or prevent one case of eclampsia is 71. In present study, the incidence of other complications of severe preeclampsia like HELLP, DIC(1% in both the groups,) and abruption (4% vs 3%), had almost equal incidence indicating prophylactic magnesium sulphate has no significant effect in controlling these complication of severe pre eclampsia .

In study by Altman 2004 [17] a quarter of women allocated magnesium sulphate had few unwanted side-effects, compared with 5% allocated placebo. The present study also had higher incidence of toxic side effects of magnesium sulphate like loss of deep tendon reflexes (20%), oliguria (24%) and other side effects like vomiting, flushing sensation (20%) in group given magnesium sulphate.

Maternal respiratory depression has been a serious concern in many studies which occurred more commonly in magnesium sulphate, administered women [17]. But in present study slightly higher rate was observed in those who were not administered magnesium sulphate (4% vs 2%).

Once magnesium sulphate crosses the placental barrier, there has been concern about its safety for the neonates. Sibai BM [18] states that prophylactic magnesium sulphate has no significant benefit in perinatal outcome when it is given to pregnant women. the confounding factors in Omu *et al.*, [12] study such as primigravidity (52%), preterm delivery (56% and 53%) in preeclamptic and eclamptic women, respectively, and intrauterine growth restriction among 30.2% of the women contributed to adverse neonatal outcome.

In the present study, overall neonatal outcome was better in group given magnesium sulphate as regards the APGAR scores, NICU admission however there were many confounding factors like pre term delivery, IUGR babies, and low birth weight to assign the effect directly to magnesium sulphate. The group given magnesium sulphate had more number of new borns of less than 32 weeks of age who were admitted to NICU (42.42% vs 5.55%) and group not given magnesium sulphate had more of new born of gestational age more than 32 weeks (94.44% vs 57.55%). When new born of more than 32 weeks alone were considered, the death rate was comparatively low in magnesium sulphate administered group (0 vs 8.8%) which is statistically significant. However, these deaths occurred remote from the time of exposure to magnesium sulphate. Hence cannot be directly attributed to be the effect of magnesium sulphate. NICU

admission rate was 21.7%, which was much higher in the control group not receiving magnesium sulphate. This high rate is comparable to that reported by Greenberg *et al.*, [19]. Similar results were found by the same authors in two different study cohorts also [20, 21].

## CONCLUSION

The study has revealed that women with severe preeclampsia, when given prophylactic magnesium sulphate before onset of imminent signs, had less chances of landing up in eclampsia and its complications, compared to the one not given. Hence administration of prophylactic magnesium sulphate to prevent eclampsia, in all cases of severe preeclampsia, even before the onset of imminent signs is justified.

## REFERENCE

1. Ascarelli, M. H., Johnson, V., May, W. L., Martin, R. W., & Martin Jr, J. N. (1998). Individually determined postpartum magnesium sulfate therapy with clinical parameters to safely and cost-effectively shorten treatment for preeclampsia. *American journal of obstetrics and gynecology*, 179(4), 952-956.
2. Witlin, A., & Sibai, B. (1998). Magnesium sulfate therapy in preeclampsia and eclampsia. *Obstetrics & Gynecology*, 92(5), 883-889.
3. Hauth, H. (2001). Hypertension disorders of pregnancy. Cunningham, F. G., Gant, N. F., & Leveno, K. G. *Obstetrics William's 21<sup>st</sup> edition* chapter 24, Mac Graw Hill, 568-609.
4. Suman, S., Shivanjali, M., Ajit, P., & Uday, P. (2003). Low dose magnesium sulphate therapy for eclampsia and imminent eclampsia: Regime tailored for Indian women. *Obstet Gynecol India*, 53(6):546-550.
5. Duley, L., & Johanson, R. (1994). Magnesium sulphate for pre- eclampsia and eclampsia: the evidence so far. *BJOG: An International Journal of Obstetrics & Gynaecology*, 101(7), 565-567.
6. Douglas, K. A., & Redman, C. W. G. (1994). Eclampsia in the united kingdom. *Bmj*, 309(6966), 1395-1400.
7. Crowther, C. A. (1985). Eclampsia at Harare Maternity Hospital. An epidemiological study. *South African medical journal= Suid-Afrikaanse tydskrif vir geneeskunde*, 68(13), 927-929.
8. Bergström, S., Povey, G., Songane, F., & Ching, C. H. O. N. G. (1992). Seasonal incidence of eclampsia and its relationship to meteorological data in Mozambique. *Journal of perinatal medicine*, 20(2), 153-158.
9. WHO, UNICEF. (1996). Revised 1990 estimates of maternal mortality: WHO/FRH/MSM/96.11. Geneva: WHO.
10. Duley, L. (1992). Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. *BJOG: An*

*International Journal of Obstetrics & Gynaecology*, 99(7), 547-553.

11. Alton, B. H., & Lincoln, G. C. (1925). The control of eclampsia convulsions by intraspinal injections of magnesium sulphate. *American Journal of Obstetrics and Gynecology*, 9(2), 167-177.
12. Omu, A. E., Al-Harmi, J., Vedi, H. L., Mlechkova, L., Sayed, A. F., & Al-Ragum, N. S. (2008). Magnesium sulphate therapy in women with pre-eclampsia and eclampsia in Kuwait. *Medical Principles and Practice*, 17(3), 227-232.
13. Magpie Trial Follow Up Study Management Group. (2004). The Magpie Trial Follow Up Study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]. *BMC pregnancy and childbirth*, 4(1), 5.
14. Sibai, B. M. (2002). The Magpie trail. *Lancet*, 30; 9342.
15. Bhattacharya, S., Naskar, A., Mondal, S., Samanta, A., & Pati, S. P. (2011). Should Magnesium Sulphate Prophylaxis be Used in all Cases of Severe Preeclampsia?. *Online Journal of Health and Allied Sciences*, 9(4), 12.
16. Sibai, B. M. (2003). Diagnosis and management of gestational hypertension and preeclampsia. *Obstetrics & Gynecology*, 102(1), 181-192.
17. Altman, D., Carroli, G., Duley, L., Farrell, B., Moodley, J., Neilson, J., & Smith, D. (2002). Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. *Lancet*, 359(9321), 1877-1890.
18. Sibai, B. M., Ewell, M., Levine, R. J., Klebanoff, M. A., Esterlitz, J., Catalano, P. M., ... & Joffe, G. (1997). Risk factors associated with preeclampsia in healthy nulliparous women. *American journal of obstetrics and gynecology*, 177(5), 1003-1010.
19. Greenberg, M. B., Penn, A. A., Thomas, L. J., El-Sayed, Y. Y., Caughey, A. B., & Lyell, D. J. (2011). Neonatal medical admission in a term and late-preterm cohort exposed to magnesium sulfate. *American journal of obstetrics and gynecology*, 204(6), 515-e1.
20. Girsan, A. I., Greenberg, M. B., El-Sayed, Y. Y., Lee, H., Carvalho, B., & Lyell, D. J. (2015). Magnesium sulfate exposure and neonatal intensive care unit admission at term. *Journal of Perinatology*, 35(3), 181-185.
21. Greenberg, M. B., Penn, A. A., Whitaker, K. R., Kogut, E. A., El-Sayed, Y. Y., Caughey, A. B., & Lyell, D. J. (2013). Effect of magnesium sulfate exposure on term neonates. *Journal of Perinatology*, 33(3), 188-193.